Treatment strategies for patients with severe aplastic anemia

Bone Marrow Transplantation

Volumn 42, Issue SUPPL.1, 2008, Pages

  Bacigalupo, A ^a  

^a Ospedele S Martino ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 3; LYMPHOCYTE ANTIBODY; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; AGE; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOL; DISEASE SEVERITY; DONOR; FAMILY; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SHORT TANDEM REPEAT; SIBLING; SURVIVAL; WHOLE BODY RADIATION;

ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 50549104303     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.113     Document Type: Review

References (24)

1. Marsh JC, Elebute MO. Stem cells in paroxysmal nocturnal haemoglobinuria and aplastic anaemia: Increasing evidence for overlap of haemopoietic defect. Transfus Med 2003; 13: 377-386.
2. Bacigalupo A, Podestà M, Raffo MR, Piaggio G, Vimercati R, Risso M et al. Lack of in vitro colony formation and myelosuppressive activity in patients with sevre aplastic anemia after autologous hematologic reconstitution. Exp Hematol 1980; 8: 795.
3. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma costitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996; 87: 4149-4157.
4. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De Flora A et al T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33 819-827.
5. Ascensao J, Kagan W, Moore M, Pahwa R, Hansen J, Good R. Aplastic, anemia: Evidence for an immunological mechanism. Lancet 1976; 1 669.
6. Young NS. Autoimmunity and its treatment in aplastic anemia. Ann Intern Med 1997; 126: 166-168.
7. Podestà M, Piaggio G, Frassoni F, Pitto A, Zikos P, Sessarego M et al. The assesment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood 1998; 91: 1959-1965.
8. Bacigalupo A, Brand R, oneto R, Bruno B, Sociè G, Passweg J et al Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation Experience. Seminars in Hematology 2000; 37: 69-80.
9. Hill RS, Petersen FB, Storb Ri Appelbaum FR, Doney K, Dahlberg S et al. Mixed hematologic chimaerism after allogeneic marrow transplant for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft -versus host disease. Blood 1986; 67: 811-816.
10. McCann S, Passweg J, Bacigalupo A, Locasciulli A, Locatelli F, Ryan J et al. The influence of cyclosporin alone, or cyclosporin and methotrexate, ion the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. Bone Marrow Transplant 2007; 39: 109-114.
11. Storb R, Erzioni R, Anasetti C, Appelbaum FR, Buckner CD, Besinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
12. Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R et al Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant 2004; 33: 9-13.
13. Pierga JY, Socie G, Gluckman E, Devergie A, Henry-Amar M, Bridier A et al. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiother Oncol 1994; 30: 55-58.
14. Locatelli F, Bruno B, Zecca M,I'Van-Lint MT, McCann S, Arcesc W et al Cyclosporin A And short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
15. Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia, minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208-215.
16. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Blood 2002; 100: 799-803.
17. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S et al Fludarabine, cyclophosphamide and antithymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947-950.
18. Guidelines. In: Schrezenmeier H, Bacigalupo A (eds). Aplastic anemia: Pathophysiology and Treatment. 2000, pp 230-257.
19. Tichelli A, Socié G, Henry-Amar M, Marsh J, Passweg J, Schrezenmeier H et al. Effectiveness of immunosuppressive thera in older patients with aplastic anemia. Ann Intern Med 1999; 130 193-201.
20. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol 1999; 107: 330-334.
21. Schrezenmeier H, Marin P, Ragavachar A, McCann S, Hows J, Gluckman E et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J of Haematol 1993; 85: 371-377.
22. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locitelli F et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients. Blood 2000; 95 1931-1934.
23. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S et al Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
24. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119: 1075-1082.